Dogan Serkan, Gurakar Ahmet
Department of Gastroenterology, Johns Hopkins School of Medicine, Maryland, United States.
Division of Gastroenterology and Hepatology, Johns Hopkins School of Medicine, Maryland, United States.
Euroasian J Hepatogastroenterol. 2015 Jul-Dec;5(2):98-106. doi: 10.5005/jp-journals-10018-1144. Epub 2016 Jul 9.
The first liver transplantation (LT) was performed by Thomas E Starzl five decades ago, and yet it remains the only therapeutic option offering gold standard treatment for end-stage liver disease (ESLD) and acute liver failure (ALF) and certain early-stage liver tumors. Post-liver transplantation survival has also dramatically improved over the last few decades despite increasing donor and recipient age and more frequent use of marginal organs to overcome the organ shortage. Currently, the overall 1 year survival following LT in the United States is reported as 85 to 90%, while the 10 years survival rate is ~50% (http://www.unos.org). The improvements are mainly due to progress in surgical techniques, postoperative intensive care, and the advent of new immunosuppressive agents. There are a number of factors that influence the outcomes prior to transplantation. Since 2002, the model for end-stage liver disease (MELD) score has been considered a predicting variable. It has been used to prioritize patients on the transplant waiting list and is currently the standard method used to assess severity in all etiologies of cirrhosis. Hepatocellular carcinoma (HCC) is the most common standard MELD exception because the MELD does not necessarily reflect the medical urgency of patients with HCC. The criteria for candidates with HCC for receiving LT have evolved over the past decade. Now, patients with HCC who do not meet the traditional Milan (MC) or UCSF criteria for LT often undergo downstaging therapy I an effort to shrink the tumor size. The shortage of donor organs is a universal problem. In some countries, the development of a deceased organ donation program has been prevented due to socioeconomic, cultural, legal and other factors. Due to the shortage of cadaveric donors, several innovative techniques have been developed to expand the organ donor pool, such as split liver grafts, marginal- or extended-criteria donors, live donor liver transplantation (LDLT), and the use of organs donated after cardiac death. Herein, we briefly summarize recent advances in knowledge related to LT. We also report common causes of death after liver transplant, including the recurrence of hepatitis C virus (HCV) and its management, and coronary artery disease (CAD), including the role of the cardiac calcium score in identifying occult CAD.
Dogan S, Gurakar A. Liver Transplantation Update: 2014. Euroasian J Hepato-Gastroenterol 2015;5(2):98-106.
五十年前,托马斯·E·斯塔兹进行了首例肝移植手术,而肝移植至今仍是为终末期肝病(ESLD)、急性肝衰竭(ALF)以及某些早期肝脏肿瘤提供金标准治疗的唯一疗法。尽管供体和受体年龄增加,且为克服器官短缺而更频繁地使用边缘器官,但在过去几十年中,肝移植后的生存率也有了显著提高。目前,美国肝移植术后1年的总体生存率据报道为85%至90%,而10年生存率约为50%(http://www.unos.org)。这些改善主要归功于手术技术的进步、术后重症监护以及新型免疫抑制剂的出现。有许多因素会影响移植前的结果。自2002年以来,终末期肝病模型(MELD)评分一直被视为一个预测变量。它被用于对移植等待名单上的患者进行优先排序,并且是目前用于评估所有肝硬化病因严重程度的标准方法。肝细胞癌(HCC)是最常见的标准MELD例外情况,因为MELD不一定能反映HCC患者的医疗紧迫性。过去十年中,HCC患者接受肝移植的标准不断演变。现在,不符合传统米兰(MC)或加州大学旧金山分校(UCSF)肝移植标准的HCC患者通常会接受降期治疗,以努力缩小肿瘤大小。供体器官短缺是一个普遍问题。在一些国家,由于社会经济、文化、法律和其他因素,尸体器官捐赠项目的发展受到了阻碍。由于尸体供体短缺,人们开发了几种创新技术来扩大器官供体库,如劈离式肝移植、边缘或扩大标准供体、活体供肝移植(LDLT)以及使用心脏死亡后捐赠的器官。在此,我们简要总结肝移植相关知识的最新进展。我们还报告了肝移植后常见的死亡原因,包括丙型肝炎病毒(HCV)复发及其管理,以及冠状动脉疾病(CAD),包括心脏钙评分在识别隐匿性CAD中的作用。
多安S,古拉卡尔A。肝移植最新进展:2014年。《欧亚肝脏胃肠病学杂志》2015年;5(2):98 - 106。